Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 in HER2 IHC3+ Advanced Colorectal Cancer
NCT07483684Phase 3Not yet recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2102 in colorectal cancer (CRC), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
TQB2102
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07483684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483684.